2023年1月20日 · 3D cultures of CD19 + B-cells induce a significant increase in B-cells and antibody production

2022年4月7日 · We report that iPSCs reprogramed from CD62L + naive and memory T cells followed by CD19-CAR engineering and 3D-organoid system differentiation confers products with conventional CD8αβ-positive CAR T cell characteristics.

Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold. CD19 is a transmembrane protein expressed on malignant B cells, but not in other lineages or other tissues, which makes it an attractive target for monoclonal antibody-mediated immunotherapy.

2020年2月6日 · Here, we successfully expressed a novel fusion construct consisting of the full-length extracellular domain of CD19 and domain 2 of human serum albumin (CD19-AD2), which was integrated into the Rosa26 bacterial artificial chromosome vector backbone for generation of a recombinant CHO-K1 production cell line.

Humanized CAR mRNA targeting CD19 was encapsulated into LNPs using microfluidic mixing, achieving efficient transfection and robust CAR expression. Engineered CAR‐T cells exhibited potent cytotoxicity against leukaemic cells in vitro, demonstrated increased cytokine secretion and enhanced tumour killing in co‐culture systems.

2022年4月7日 · We report that iPSCs reprogramed from CD62L + naive and memory T cells followed by CD19-CAR engineering and 3D-organoid system differentiation confers products with conventional CD8αβ-positive CAR T cell characteristics.

Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scFv) in current use. As such, further investigation of CARs recognize different epitopes of CD19 antigen may be necessary.

CAR T cells targeting CD19 were the first to achieve dramatic clinical responses in patients with relapsed/refractory B cell malignancies and to be approved by the U.S. Food and Drug Administration (FDA).

2022年10月8日 · 我们报道了从CD62L+幼稚T细胞和记忆T细胞中重新编程的诱导多能干细胞，然后进行CD19-CAR工程和3D类器官系统分化，获得了具有传统CD8αβ阳性CAR-T细胞特征的产物。 与传统的CD19-CAR-T细胞相比，扩展的iPSC CD19-CAR T细胞具有相当的抗原特异性激活、脱颗粒、细胞毒性和细胞因子分泌，并保持了来自最初克隆的TCR的同质表达。 iPSC CD19-CAR T细胞在体内也介导了强大的抗肿瘤活性，延长了CD19+人肿瘤异种移植物小鼠的存活时间。 …

CD19 - Explore an overview of CD19, with a histogram displaying coding mutations, full tabulated details of all associated variants, tissue distribution and any drug resistance data.